CH BIOTECH SER (08037) Announces Interim Results with Loss Attributable to Owners of HK$32.006 Million, Narrowing 59.95% Year-on-Year
Stock News
Aug 27
CH BIOTECH SER (08037) announced its interim results for 2025, reporting revenue of HK$38.872 million, representing a year-on-year increase of 19.79%. The loss attributable to owners of the company was HK$32.006 million, narrowing by 59.95% compared to the same period last year. Loss per share stood at HK$0.033.
According to the announcement, the improvement in losses was primarily attributed to the company's successful implementation of cost control measures, which led to an increase in gross profit margin and a reduction in administrative expenses. Additionally, the company received compensation income of approximately HK$13.7 million from insurance claims related to damage caused by heavy rainfall to the Hainan construction site in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.